Factors affecting survival after concurrent chemoradiation therapy for advanced hepatocellular carcinoma: a retrospective study

Table 5 Predictors of overall survival

Characteristic	Univariate			Multivariate
Characteristic	Hazard ratio	95% CI	P-value	Hazard ratio	95% CI	P-value
Age (per year)	0.990	0.952-1.029	0.601
Gender (male vs. female)	0.778	0.269-2.246	0.641
Liver cirrhosis (with vs. without)	1.011	0.430-2.377	0.980
Child-Pugh class (A vs.B)	0.245	0.090-0.668	0.003	0.436	0.155-1.226	0.116
Main portal trunk invasion (with vs. without)	2.079	1.019-4.243	0.040	2.099	0.941-4.682	0.070
Node metastasis (with vs. without)	0.732	0.350-1.531	0.405
Baseline tumor size (per 1 cm)	0.912	0.830-1.002	0.056
Baseline AFP (per 100 ng/mL)	1.000	0.998-1.003	0.711
Baseline DCP (per 100 mAU/mL)	1.001	0.999-1.002	0.256
Radiation dose (per 100 cGy)	1.007	0.943-1.074	0.843
Objective response after CCRT (with vs. without)	0.096	0.036-0.254	<0.001	0.028	0.005-0.148	<0.001
AFP after CCRT (per 100 ng/mL)	1.000	0.998-1.003	0.702
DCP after CCRT (per 100 mAU/mL)	1.003	1.001-1.004	0.001
Additional TACE (with vs. without)	0.296	0.137-0.641	0.001	0.134	0.047-0.383	<0.001
Round of HAIC	0.805	0708-0.915	0.001	0.742	0.626-0.880	0.001

AFP α-fetoprotein, DCP Des-gamma carboxyprothrombin, CCRT Concurrent chemoradiation therapy, TACE Transarterial chemoembolization, HAIC Hepatic arterial infusional chemotherapy

ISSN: 1748-717X